Skip to main content
Log in

Erythropoietin prescribing: financial incentives outweigh safety risks?

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. see Reactions 1143 p2; 801013918

Reference

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erythropoietin prescribing: financial incentives outweigh safety risks?. Reactions Weekly 1457, 1 (2013). https://doi.org/10.1007/s40278-013-3856-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-013-3856-5

Navigation